- Trial will evaluate IDE161, IDEAYA's investigational PARG
inhibitor, in combination with
KEYTRUDA® (pembrolizumab), Merck's anti-PD-1
therapy, in patients with MSI-high and MSS endometrial cancer
- Potential first-in-class PARG inhibitor, in combination
with anti-PD-1 therapy, targets two complementary mechanisms of
anti-tumor immune response in endometrial cancer
- IDEAYA will sponsor the clinical trial and Merck will provide
KEYTRUDA
SOUTH SAN FRANCISCO, Calif.,
March 12, 2024 /PRNewswire/ -- IDEAYA
Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology
company committed to the discovery and development of targeted
therapeutics, today announced that it has entered into a
clinical trial collaboration and supply agreement with Merck (known
as MSD outside the US and Canada) to evaluate IDE161, the
company's investigational, potential first-in-class, small molecule
poly (ADP-ribose) glycohydrolase, or PARG, inhibitor, in
combination with KEYTRUDA® (pembrolizumab) Merck's
anti-PD-1 therapy, in patients with microsatellite instability-, or
MSI-, high and microsatellite stable, or MSS, endometrial cancer,
in a Phase 1 clinical trial.
"We are excited to enter this collaboration as it allows study
within and beyond the homologous recombination deficient (HRD)
setting in endometrial cancer," said Darrin
Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA
Biosciences. "We are very pleased to collaborate with Merck on this
trial evaluating IDE161 in combination with KEYTRUDA in patients
with MSI-high and MSS endometrial cancer. IDEAYA's IDE161
combination strategy is focused on advancing multiple high
conviction rational combinations, including beyond the HRD
biomarker setting," said Yujiro S.
Hata, President and Chief Executive Officer, IDEAYA
Biosciences.
IDE161 is a small molecule inhibitor targeting PARG, that is
being evaluated in a Phase 1 clinical trial, which is currently in
its monotherapy expansion stage. The trial is strategically focused
on estrogen receptor positive (ER+), human epidermal growth factor
receptor 2 negative (Her2-) breast cancer with HRD, as well as
other solid tumors with HRD, such as endometrial cancer, colorectal
cancer and prostate cancer. In parallel, IDEAYA is continuing with
a Phase 1 dose optimization. Of note, multiple partial responses by
RECIST 1.1. and tumor shrinkage in priority solid tumor types were
observed early in the Phase 1 dose escalation and dose expansion.
IDE161 received the U.S. Food & Drug Administration Fast-Track
designation for BRCA1/2 ovarian and breast cancers.
KEYTRUDA® is a registered trademark of Merck
Sharp & Dohme LLC, a subsidiary of Merck & Co.,
Inc., Rahway, NJ, USA.
Under the clinical trial collaboration and supply agreement,
Merck will provide KEYTRUDA to IDEAYA, which will be the sponsor of
the Phase 1 clinical combination trial. IDEAYA and Merck each
retain all commercial rights to their respective compounds,
including as monotherapy or as combination therapies. The
mechanistic rationale and preclinical data to support the IDE161
and PD-1 clinical combination will be provided as part of a future
R&D update.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's approach
integrates capabilities in identifying and validating translational
biomarkers with drug discovery to select patient populations most
likely to benefit from its targeted therapies. IDEAYA is applying
its research and drug discovery capabilities to synthetic lethality
– which represents an emerging class of precision medicine
targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related the potential
therapeutic benefits of IDE161 in combination with KEYTRUDA. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's recent
Annual Report on Form 10-K filed on February
20, 2024 and any current and periodic reports filed with the
U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-clinical-collaboration-to-evaluate-ide161-in-combination-with-keytruda-pembrolizumab-in-patients-with-endometrial-cancer-302085972.html
SOURCE IDEAYA Biosciences, Inc.
